Evolutionary history and metabolic insights of ancient mammalian uricases.
Level 5 - mechanism / opinion, no new human data
Level 5 by CEBM rules: bench, computational, cell culture, and animal research with no human clinical data.
PubMed 24550457 · doi:10.1073/pnas.1320393111
What was done
Evolutionary models were applied to reconstruct and resurrect ancestral mammalian uricase intermediates preceding gene pseudogenization in primates. Researchers determined the 3D crystal structure of a mammalian uricase to map evolutionary amino acid replacements. They stably transfected ancient and modern uricase variants into HepG2 liver cells to examine the hypothesis that uricase loss promoted fructose-to-fat conversion, and tested the pharmacokinetics of an ancient uricase injected into rodents.
What was found
The abstract reports directional findings without quantitative metrics. Resurrected ancestral uricases showed a steady decrease in catalytic activity from the last common mammalian ancestor into descendent primate lineages prior to complete pseudogenization. Cell culture and rodent pharmacokinetic experiments demonstrated metabolic effects related to fructose handling and suggested the feasibility of engineered ancestral enzymes for hyperuricemia-related conditions.
Why it matters
This study provides molecular and structural evidence for the gradual evolutionary decline of uricase activity in ancestral primates, offering mechanistic context for human uric acid regulation. It also highlights ancestral protein resurrection as a potential strategy for designing uricase therapies for gout and tumor lysis syndrome.
Limits
The abstract reports no exact numerical values, sample sizes, kinetic constants, or pharmacokinetic parameters. Biological inferences rely on computational evolutionary reconstructions, a single hepatoma cell line (HepG2), and rodent models, which cannot fully replicate ancestral primate physiology or prove clinical efficacy in humans.
Cited by
- supports Resurrecting ancestral uricase and inserting it into human liver cells suppresses the large fat-accumulation response seen when uricase-deficient human liver cells are exposed to fructose.